Access the full text.
Sign up today, get DeepDyve free for 14 days.
E Cantó, JC Alvarez-Cermeño, LM Villar, M Tintoré, X Montalban (2010)
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosisBrain, 133
T Rosenling, MP Stoop, A Attali, H Aken, E Suidgeest, C Christin, C Stingl, F Suits, P Horvatovich, RQ Hintzen, T Tuinstra, R Bischoff, TM Luider (2012)
Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosisJ Proteome Res, 11
LM Watkins, JW Neal, S Loveless, I Michailidou, V Ramaglia, MI Rees, R Reynolds, NP Robertson, BP Morgan, OW Howell (2016)
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsJ Neuroinflammation, 13
BN Hammack, GP Owens, MP Burgoon, DH Gilden (2003)
Improved resolution of human cerebrospinal fluid proteins on two-dimensional gelsMult Scler, 9
KH Ko, QL Lam, M Zhang, CK Wong, CK Lo, M Kahmeyer-Gabbe, WH Tsang, SL Tsang, LC Chan, MH Sham, L Lu (2007)
Hoxb3 deficiency impairs B lymphopoiesis in mouse bone marrowExp Hematol, 35
JR Wiśniewski, A Zougman, N Nagaraj, M Mann (2009)
Universal sample preparation method for proteome analysisNat Methods, 6
O Lindblad, RA Chougule, SA Moharram, NN Kabir, J Sun, JU Kazi, L Rönnstrand (2015)
The role of HOXB2 and HOXB3 in acute myeloid leukemiaBiochem Biophys Res Commun, 467
B Bodey, B Bodey, SE Siegel, HE Kaiser (2000)
Immunocytochemical detection of the homeobox B3, B4, and C6 gene products within the human thymic cellular microenvironmentIn Vivo, 14
JA Opsahl, M Vaudel, A Guldbrandsen, E Aasebø, V Pesch, D Franciotta, KM Myhr, H Barsnes, M Berle, Ø Torkildsen, AC Kroksveen, FS Berven (2016)
Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosisProteomics, 16
B Amin, A Maurer, W Voelter, A Melms, H Kalbacher (2014)
New potential serum biomarkers in multiple sclerosis identified by proteomic strategiesCurr Med Chem, 21
B Ferguson, MK Matyszak, MM Esiri, VH Perry (1997)
Axonal damage in acute multiple sclerosis lesionsBrain, 120
MC Beker, B Caglayan, E Yalcin, AB Caglayan, S Turkseven, B Gurel, T Kelestemur, E Sertel, Z Sahin, S Kutlu, U Kilic, AT Baykal, E Kilic (2017)
Time-of-day dependent neuronal injury after ischemic stroke: implication of circadian clock transcriptional factor bmal1 and survival kinase AKTMol Neurobiol
T Avsar, İM Durası, U Uygunoğlu, M Tütüncü, NO Demirci, S Saip, OU Sezerman, A Siva, E Tahir Turanlı (2015)
CSF proteomics identifies specific and shared pathways for multiple sclerosis clinical subtypesPLoS One, 10
G Hinsinger, N Galéotti, N Nabholz, S Urbach, V Rigau, C Demattei, S Lehmann, W Camu, P Labauge, G Castelnovo, D Brassat, D Loussouarn, M Salou, D Laplaud, O Casez, J Bockaert, P Marin, E Thouvenot (2015)
Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosisMult Scler, 21
R Balabanov, D Lisak, T Beaumont, RP Lisak, P Dore-Duffy (2001)
Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1)Clin Diagn Lab Immunol, 6
J Chen, S Zhu, N Jiang, Z Shang, C Quan, Y Niu (2013)
HoxB3 promotes prostate cancer cell progression by transactivating CDCA3Cancer Lett, 330
CH Polman, SC Reingold, B Banwell, M Clanet, JA Cohen, M Filippi, K Fujihara, E Havrdova, M Hutchinson, L Kappos, FD Lublin, X Montalban, P O’Connor, M Sandberg-Wollheim, AJ Thompson, E Waubant, B Weinshenker, JS Wolinsky (2011)
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol, 69
S Mi, X Lee, Y Hu, B Ji, Z Shao, W Yang, G Huang, L Walus, K Rhodes, BJ Gong, RH Miller, RB Pepinsky (2011)
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelinationNat Med, 17
PK Stys, GW Zamponi, J Minnen, JJ Geurts (2012)
Will the real multiple sclerosis please stand up? Nature reviewsNeuroscience, 13
D Ribatti, P Iaffaldano, C Marinaccio, M Trojano (2016)
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patientsClin Exp Med, 16
J Füvesi, J Hanrieder, K Bencsik, C Rajda, SK Kovács, L Kaizer, S Beniczky, L Vécsei, J Bergquist (2012)
Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosisInt J Mol Sci, 13
N Miyake, K Miyake, S Karlsson, T Shimada (2010)
Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cellsMol Ther, 18
DH Miller, SM Leary (2007)
Primary-progressive multiple sclerosisLancet Neurol, 6
H Tumani, V Lehmensiek, D Rau, I Guttmann, G Tauscher, H Mogel, C Palm, V Hirt, SD Suessmuth, I Sapunova-Meier, AC Ludolph, J Brettschneider (2009)
CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosisNeurosci Lett, 452
T Demircan, I Keskin, SN Dumlu, N Aytürk, ME Avşaroğlu, E Akgün, G Öztürk, AT Baykal (2017)
Detailed tail proteomic analysis of axolotl (Ambystoma mexicanum) using an mRNA-seq reference databaseProteomics, 17
D Dumont, JP Noben, J Raus, P Stinissen, J Robben (2004)
Proteomic analysis of cerebrospinal fluid from multiple sclerosis patientsProteomics, 4
A Siva (2006)
The spectrum of multiple sclerosis and treatment decisionsClin Neurol Neurosurg, 108
AC Kroksveen, JD Jaffe, E Aasebø, H Barsnes, Y Bjørlykke, D Franciotta, H Keshishian, KM Myhr, JA Opsahl, V Pesch, CE Teunissen, Ø Torkildsen, RJ Ulvik, H Vethe, SA Carr, FS Berven (2015)
Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosisProteomics, 15
AC Kroksveen, JA Opsahl, TT Aye, RJ Ulvık, FS Berven (2011)
Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomicsJ Proteomics, 74
P Sarchielli, M Filippo, MV Ercolani, D Chiasserini, A Mattioni, M Bonucci, S Tenaglia, P Eusebi, P Calabresi (2008)
Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patientsNeurosci Lett, 435
A Compston, A Coles (2008)
Multiple sclerosisLancet, 372
L Novakova, M Axelsson, M Khademi, H Zetterberg, K Blennow, C Malmeström, F Piehl, T Olsson, J Lycke (2017)
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosisJ Neurochem, 141
D Miller, F Barkhof, X Montalban, A Thompson, M Filippi (2005)
Clinically isolated syndromes suggestive of multiple sclerosis. Part I. Natural history, pathogenesis, diagnosis, and prognosisLancet Neurol, 4
WI McDonald, A Compston, G Edan, D Goodkin, HP Hartung, FD Lublin, HF McFarland, DW Paty, CH Polman, SC Reingold, M Sandberg-Wollheim, W Sibley, A Thompson, S Noort, BY Weinshenker, JS Wolinsky (2001)
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosisAnn Neurol, 50
J Gobom (2015)
Advancing cerebrospinal fluid biomarker discovery by mass spectrometryNeurodegener Dis Manag, 5
G Comi, M Filippi, F Barkhof, L Durelli, G Edan, O Fernández, H Hartung, P Seeldrayers, PS Sørensen, M Rovaris, V Martinelli, OR Hommes (2001)
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyLancet, 357
JP Noben, D Dumont, N Kwasnikowska, P Verhaert, V Somers, R Hupperts, P Stinissen, J Robben (2006)
Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometryJ Proteome Res, 5
Multiple sclerosis (MS) often starts in the form of clinically isolated syndrome (CIS) and only some of the CIS patients progress to relapsing-remitting MS (RRMS). Biomarkers to predict conversion from CIS to MS are thus greatly needed for making correct treatment decisions. To identify a predictive cerebrospinal fluid (CSF) protein, we analyzed the first-attack CSF samples of CIS patients who converted (CIS–MS) (n = 23) and did not convert (CIS–CIS) (n = 19) to RRMS in a follow-up period of 5 years using proteomics analysis by liquid chromatography tandem-mass spectrometry (LC–MS/MS) and verified by ELISA. Label-free differential proteomics analysis of CSF ensured that 637 proteins were identified and 132 of these proteins were found to be statistically significant. Further investigation with the ingenuity pathway analysis (IPA) software led to identification of three pathway networks mostly comprised proteins involved in inflammatory response, cellular growth and tissue proliferation. CSF levels of four of the most differentially expressed proteins belonging to the cellular proliferation network function, chitinase-3-like protein 1 (CHI3L1), tumor necrosis factor receptor superfamily member 21 (TNFRSF21), homeobox protein Hox-B3 (HOXB3) and iduronate 2-sulfatase (IDS), were measured by ELISA. CSF levels of HOXB3 were significantly increased in CIS–MS patients. Our results indicate that cell and tissue proliferation functions are dysregulated in MS as early as the first clinical episode. HOXB3 has emerged as a potential novel biomarker which might be used for prediction of CIS–MS conversion.
Acta Neurologica Belgica – Springer Journals
Published: Jun 5, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.